Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith

Research output: Contribution to journalArticle

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)3132-3135
Number of pages4
JournalBlood Advances
Volume3
Issue number20
DOIs
StatePublished - Oct 22 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Kamdar, M., Li, H., Chen, R. W., Rimsza, L. M., Leblanc, M. L., Fenske, T. S., Shea, T. C., Barr, P. M., Phillips, T. J., Leonard, J. P., Kahl, B. S., Friedberg, J. W., & Smith, S. M. (2019). Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances, 3(20), 3132-3135. https://doi.org/10.1182/bloodadvances.2019000526